Positioning Anti-Il-12 And Anti-Il-23 Inhibitors

Positioning anti-IL-12 and anti-IL-23 inhibitors

IL23 & IL12/23 Inhibitors: An Overview

AlbertaRheumatology

IBD: Safety and Positioning of IL-23 Inhibitors Under Investigation

Targeting the IL-12/23 Pathway in IBD

Advances in Anti-Cytokine Therapy: New Pathways (IL 12/23, IL17, IL23)

ClevelandClinicCME

New Biologic Therapies that Target the IL-12/23 Pathway

Advances in Anti-Cytokine Therapy for IBD: The Role of IL-12/23 and IL-23 Inhibitors

Understanding the use of IL12/IL23 targeted biologics

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab

Annals of the Rheumatic Diseases

IL-23 Inhibitors and Other Emerging Psoriasis Treatments

ClevelandClinicCME

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Long-term persistence and effectiveness of IL-12/23 pathway inhibitor ustekinumab and TNF inhibitors

Annals of the Rheumatic Diseases

Use of IL-23 Inhibitors to Treat Plaque Psoriasis

IL-23: Long-term Data and Safety Data

IL-12/23 Blockers: First- or Second-Line Option in Plaque Psoriasis

WCH23: IL-17 vs IL-23 Blockers – Why and When?

IL-12/23 Inhibitors and Small Molecule Inhibitors

ClevelandClinicCME

Novel Targets and Therapeutic Perspectives in IBD: Beyond Anti-TNF

Safety and Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Mechanisms of Disease: Biologic Pipeline for IBD